Artax Biopharma
Monday, June 03, 2024
Company Presentation
![Immunology](https://cdn.asp.events/CLIENT_BIO_7BB99CBA_BAD1_B8C8_CF9F25DA29A80CC6/sites/BIOIC-2024/media/icons/seminars/immunology.png)
Company Presentation Theater 2
Artax Biopharma is a clinical-stage biotechnology company transforming the treatment of T Cell-driven autoimmune diseases. Our first-in-class oral small molecules aim to deliver immune system modulation without immunosuppression, potentially unlocking new treatment options.
Our lead program AX-158 will deliver results in a Phase 2a Proof of Concept study in psoriasis later in 2024. In contrast to agents targeting individual cytokines, we believe our approach will allow us to address a broad spectrum of patients. By having the potential to impact multiple cytokines, we hope to address areas of high unmet need beyond where targeted therapies have achieved success.
![Artax Biopharma](https://www.abstractscorecard.com/uploads/Tasks/upload/21754/XDQDGWMO-1768743-1-JPG(1).png)
Company Website:
https://artaxbiopharma.com/
Lead Product in Development:
AX-158
Company HQ City
Cambridge
Company HQ State
Massachusetts
Company HQ Country
United States
CEO/Top Company Official
Robert Armstrong, PhD
Development Phase of Primary Product
Phase II
Primary Speaker